Counselors in Belcamp, MD Accepting Medicare

8 Counselors found. Showing 1 - 8

Emily Smith, ADT Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1361 Brass Mill Rd Ste A, Belcamp, MD 21017 Phone: 410-273-9700

Felicia Abass Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1361 Brass Mill Rd, Belcamp, MD 21017 Phone: 410-273-9700    Fax: 410-273-9713

Mrs. Gale Dollard, LGPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1200 Brass Mill Rd, Suite A, Belcamp, MD 21017 Phone: 410-935-1489

Mary Lynn Panowitz, CSCAD Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1361 Brass Mill Rd Ste A, Belcamp, MD 21017 Phone: 410-273-9700    Fax: 410-273-9713

Anthony Avolio, CAC-AD Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1361 Brass Mill Rd Ste A, Belcamp, MD 21017 Phone: 410-273-9700

Mrs. Tina Marie Ray, CT-ADT Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1361 Brass Mill Rd, Belcamp, MD 21017 Phone: 410-273-9700    Fax: 410-273-9713

Jennifer Courtney, CAC-AD Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1361 Brass Mill Rd Ste A, Belcamp, MD 21017 Phone: 410-273-9700

Ms. Kelly Marie Jenssen, LGPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1402 Allwood Ln Apt 203, Belcamp, MD 21017 Phone: 908-310-4116

News Archive

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

Mayo Clinic selected for Healthcare Internet Hall of Fame Class of 2012

​Mayo Clinic has been inducted into the Healthcare Internet Hall of Fame Class of 2012 at the 16th Annual Healthcare Internet Conference in Las Vegas. Mayo is one of two organizations that received the honor for Innovative Products and Services. Additionally, Mayo Clinic was honored with five eHealthcare Leadership Awards, presented by eHealthcare Strategy & Trends.

Seniors cite financial need as the greatest barrier to receiving dental care

A survey of seniors' access to dental care conducted by researchers at the University at Buffalo and Buffalo State College presents a sobering picture of the dental needs and barriers to dental care experienced by seniors.

Study reveals neurobehavioral impact of chronic alcohol-vapor exposure during adolescence

The developmental period from adolescence to adulthood is accompanied by a greater vulnerability to addictions – including alcohol use disorders – than is seen in other periods of life.

New aspirational statement to guide the development of AI in radiology published

Experts in the use of artificial intelligence (AI) in radiology, from many of the world's leading radiology, medical physics and imaging informatics groups, today published an aspirational statement to guide the development of AI in radiology.

Read more Medical News

› Verified 3 days ago